1. Search Result
Search Result
Results for "

dopamine neurons

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

1

Screening Libraries

2

Fluorescent Dye

2

Biochemical Assay Reagents

1

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W010410

    Others Neurological Disease Metabolic Disease
    Oct-1-en-3-ol, a fatty acid fragrant, is a self-stimulating oxylipin messenger. Oct-1-en-3-ol serves as a signaling molecule in plant cellular responses, plant-herbivore interactions, and plant-plant interactions. Oct-1-en-3-ol causes dopamine neuron degeneration through disruption of dopamine handling .
    Oct-1-en-3-ol
  • HY-N0137

    Others Neurological Disease
    Tetrahydropapaverine hydrochloride is one of the Tetrahydroisoquinolines. Tetrahydropapaverine hydrochloride has neurotoxic effects on dopamine neurons .
    Tetrahydropapaverine hydrochloride
  • HY-121685A

    Potassium Channel Neurological Disease
    Tipepidine hydrochloride reversibly inhibits dopamine (DA) D2 receptor-mediated GIRK currents (IDA(GIRK)) with an IC50 of 7.0 μM. Tipepidine hydrochloride subsequently activates VTA dopamine neuron . Tipepidine hydrochloride, a non-narcotic antitussive, exerts an antidepressant-like effect .
    Tipepidine hydrochloride
  • HY-N7063S1

    Mitochondrial Metabolism Fungal Endogenous Metabolite Reactive Oxygen Species Isotope-Labeled Compounds Infection
    Nerol-d6 is deuterated labeled Oct-1-en-3-ol (HY-W010410). Oct-1-en-3-ol, a fatty acid fragrant, is a self-stimulating oxylipin messenger. Oct-1-en-3-ol serves as a signaling molecule in plant cellular responses, plant-herbivore interactions, and plant-plant interactions. Oct-1-en-3-ol causes dopamine neuron degeneration through disruption of dopamine handling .
    Nerol-d6
  • HY-121685

    Potassium Channel Neurological Disease
    Tipepidine reversibly inhibits dopamine (DA) D2 receptor-mediated GIRK currents (IDA(GIRK)) with an IC50 of 7.0 μM. Tipepidine subsequently activates VTA dopamine neuron . Tipepidine, a non-narcotic antitussive, exerts an antidepressant-like effect .
    Tipepidine
  • HY-N0137A

    Others Neurological Disease
    (R)-Tetrahydropapaverine hydrochloride is the isomer of Tetrahydropapaverine hydrochloride (HY-N0137), and can be used as an experimental control. Tetrahydropapaverine hydrochloride is one of the Tetrahydroisoquinolines. Tetrahydropapaverine hydrochloride has neurotoxic effects on dopamine neurons .
    (R)-Tetrahydropapaverine hydrochloride
  • HY-138806

    Others Neurological Disease
    PAQ (Compound 4c) is a quinoxaline derivative. PAQ is an orally active neuroprotective agent, which targets dopamine (DA) neurons and activates reticulum endoplasmic ryanodine receptor (RyR) channels, without effects on glia cells .
    PAQ
  • HY-W008719
    MPP+ iodide
    5+ Cited Publications

    Mitochondrial Metabolism Neurological Disease
    MPP+ iodide, a toxic metabolite of the neurotoxin MPTP, causes symptom of Parkinson's disease in animal models by selectively destroying dopaminergic neurons in substantia nigra. MPP+ iodide is taken up by the dopamine transporter into dopaminergic neurons where it exerts its neurotoxic action on mitochondria by affecting complex I of the respiratory chain. MPP+ iodide is also a high affinity substrate for the serotonin transporter (SERT) .
    MPP+ iodide
  • HY-124767

    Others Neurological Disease
    SR 142948A is a non-peptide neuropeptide neuropeptin (NT) receptor antagonist. SR 142948A is able to bind to neuropeptin receptors, especially with high affinity for NT1 and NT2 receptors. SR 142948A is mainly used to study the role of neuropeptide in the neurotransmitter system, especially the dopamine system .
    SR 142948A
  • HY-W026109

    Fat Mass and Obesity-associated Protein (FTO) Neurological Disease
    FTO-IN-12 (Compound 2) is an inhibitor of fat mass and obesity-related protein (FTO). Kd and IC50 values are 185 nM and 1.46 μM, respectively. FTO-IN-12 can be used in the study of neurodegenerative diseases .
    FTO-IN-12
  • HY-W008719S

    Mitochondrial Metabolism Neurological Disease
    MPP+-d3 (iodide) is deuterium labeled MPP+ (iodide). MPP+ iodide, a toxic metabolite of the neurotoxin MPTP, causes symptom of Parkinson's disease in animal models by selectively destroying dopaminergic neurons in substantia nigra. MPP+ iodide is taken up by the dopamine transporter into dopaminergic neurons where it exerts its neurotoxic action on mitochondria by affecting complex I of the respiratory chain. MPP+ iodide is also a high affinity substrate for the serotonin transporter (SERT)[1][2].
    MPP+-d3(iodide)
  • HY-160019

    Deubiquitinase Mitophagy Neurological Disease
    MTX115325 (Example 1) is an orally active, brain-penetrating USP30 inhibitor (IC50=12 nM) with neuroprotective activity. MTX115325 increases ubiquitination (EC50=32 nM) of the mitochondrial outer membrane protein TOM20 (a USP30 substrate), increasing mitophagy. MTX115325 prevents dopaminergic neuron loss and preserves striatal dopamine .
    MTX115325
  • HY-152171

    Monoamine Transporter Neurological Disease
    GZ-11608 is a potent and selective vesicular monoamine transporter-2 (VMAT2) inhibitor with high affinity (Ki = 25 nM). GZ-11608 decreases methamphetamine-induced dopamine release from isolated synaptic vesicles from brain dopaminergic neurons. GZ-11608 exhibits rapid brain penetration and without neurotoxicity. GZ-11608 can be used for the research of methamphetamine use disorder .
    GZ-11608
  • HY-136390

    Dopamine Receptor Neurological Disease
    ML417 is a selective and brain penetrant D3 dopamine receptor (D3R) agonist, with an EC50 of 38 nM. ML417 potently promotes D3R-mediated β-arrestin translocation, G protein mediated signaling, and pERK phosphorylation with minimal effects on other GPCR-mediated signaling. ML417 exhibits neuroprotection against toxin-induced neurodegeneration of dopaminergic neurons .
    ML417
  • HY-116451
    PF-04859989 hydrochloride
    1 Publications Verification

    Others Neurological Disease
    PF-04859989 hydrochloride is a brain-penetrant, irreversible kynurenine aminotransferase (KAT) II inhibitor with IC50s of 23 and 263 nM for hKAT II and rKAT II. PF-04859989 hydrochloride is selective for KAT II over human KAT I, KAT III, and KAT IV (IC50s of 22, 11, and >50 μM, respectively) .
    PF-04859989 hydrochloride
  • HY-113967

    Others Neurological Disease
    PF-04859989 is a brain-penetrant, irreversible kynurenine aminotransferase (KAT) II inhibitor with IC50s of 23 and 263 nM for hKAT II and rKAT II. PF-04859989 is selective for KAT II over human KAT I, KAT III, and KAT IV (IC50s of 22, 11, and >50 μM, respectively) .
    PF-04859989
  • HY-B1081
    Oxidopamine hydrochloride
    Maximum Cited Publications
    15 Publications Verification

    6-Hydroxydopamine Hydrochloride

    Dopamine Receptor Autophagy Mitophagy COX PGE synthase Interleukin Related p38 MAPK Apoptosis Caspase Neurological Disease Cancer
    Oxidopamine (6-OHDA) hydrochloride is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrochloride is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrochloride promotes COX-2 activation, leading to PGE2 synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrochloride can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome .
    Oxidopamine hydrochloride
  • HY-B1081A
    Oxidopamine hydrobromide
    Maximum Cited Publications
    15 Publications Verification

    6-Hydroxydopamine hydrobromide; 6-OHDA hydrobromide

    Dopamine Receptor Autophagy Mitophagy COX PGE synthase Interleukin Related p38 MAPK Apoptosis Caspase Neurological Disease Cancer
    Oxidopamine (6-OHDA) hydrobromide is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrobromide is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrobromide promotes COX-2 activation, leading to PGE2 synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrobromide can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome .
    Oxidopamine hydrobromide
  • HY-148502

    mAChR Neurological Disease
    VU6019650 is a potent and selective orthosteric antagonist of M5 mAChR (IC50=36 nM), can be used for opioid use disorder (OUD) relief. VU6019650 can cross blood brain barrier, potentially modulates the mesolimbic dopaminergic reward circuitry. VU6019650 blocks Oxotremorine M iodide (HY-101372A) induced increases of neuronal firing rates of midbrain dopamine neurons in the ventral tegmental area (VTA) .
    VU6019650
  • HY-160959

    nAChR Neurological Disease
    AN317 is a selective agonist for α6β2-containing nicotinic acetylcholine receptor (nAChR) with Ki of 6.2 nM and 4.1 nM, for α6/α3β2β3 receptor and α4β2 receptor, respectively. AN317 induces dopamine release in the synaptosomes of the rat striatum, enhances dopaminergic neuronal activity in substantia nigra, and exhibits protective efficacy to rat neurons against dopamine neurotoxin MPP +. AN317 exhibits good pharmacokinetic characteristics in rats. AN317 penetrates the blood-brain barrier (BB) .
    AN317
  • HY-10431G

    TGF-β Receptor Neurological Disease Cancer
    SB-431542 (GMP) is SB-431542 (HY-10431) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SB-431542 is a TGF-β receptor kinase inhibitor (TRKI) in SMAD signaling .
    SB-431542
  • HY-15147G

    PARP Neurological Disease Cancer
    XAV-939 (GMP) is XAV-939 (HY-15347) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. XAV-939 is a tankyrase inhibitor .
    XAV-939
  • HY-13409
    SB 242084
    4 Publications Verification

    5-HT Receptor Neurological Disease Metabolic Disease
    SB 242084 is a selective, competitive and high-affinity (pKi=9.0) 5-HT2C receptor antagonist (crosses the blood-brain barrier). SB 242084 increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 also increases mitochondrial gene expression and oxidative metabolism via 5-HT2A receptor. SB 242084 has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage .
    SB 242084
  • HY-13409A
    SB 242084 dihydrochloride
    4 Publications Verification

    5-HT Receptor Neurological Disease Metabolic Disease
    SB 242084 dihydrochloride is a selective, competitive and high-affinity (pKi=9.0) 5-HT2C receptor antagonist (crosses the blood-brain barrier). SB 242084 dihydrochloride increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 dihydrochloride also increases mitochondrial gene expression and oxidative metabolism via 5-HT2A receptor. SB 242084 dihydrochloride has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage .
    SB 242084 dihydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: